Evidence map›Paper›PMID 32914017›Full record

ArticleJCO precision oncology2019

Crizotinib and Surgery for Long-Term Disease Control in Children and Adolescents With ALK-Positive Inflammatory Myofibroblastic Tumors.

Toby Trahair, Andrew J Gifford, Ashleigh Fordham, Chelsea Mayoh, Mitali Fadia, Robyn Lukeis, Andrew C Wood, Santosh Valvi, Roderick D Walker, James Blackburn and 5 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JCO precision oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Update of Diagnosis and Targeted Therapy for ALKCurrent treatment options in oncology · 2023
    Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 9 institutions in 3 countries.

Toby TrahairSydney Children's Hospital, Randwick, New South Wales, Australia.
Andrew J GiffordChildren's Cancer Institute, Sydney, New South Wales, Australia.
Ashleigh FordhamChildren's Cancer Institute, Sydney, New South Wales, Australia.
Chelsea MayohChildren's Cancer Institute, Sydney, New South Wales, Australia.
Mitali FadiaCanberra Hospital, Garran, Australian Capital Territory, Australia.
Robyn LukeisSt Vincent's Hospital, Darlinghurst, New South Wales, Australia.
Andrew C WoodUniversity of Auckland, Auckland, New Zealand.
Santosh ValviPerth Children's Hospital, Perth, Western Australia, Australia.
Roderick D WalkerQueensland Children's Hospital, South Brisbane, Queensland, Australia.
James BlackburnUniversity of New South Wales, Sydney, New South Wales, Australia.
Erin E HeyerGarvan Institute of Medical Research, Sydney, New South Wales, Australia.
Tim R MercerUniversity of New South Wales, Sydney, New South Wales, Australia.
Draga BarbaricSydney Children's Hospital, Randwick, New South Wales, Australia.
Glenn M MarshallSydney Children's Hospital, Randwick, New South Wales, Australia.
Karen L MacKenzieChildren's Medical Research Institute, Westmead New South Wales, Australia.
Children's Cancer Institute Australia · AUGarvan Institute of Medical Research · AUSydney Children's Hospital · AUCanberra Hospital · AUChildren's Medical Research Institute · AUPrincess Margaret Hospital for Children · AUQueensland Children’s Hospital · AUSt Vincent's Hospital Sydney · AUUniversity of Auckland · NZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeBefore anaplastic lymphoma kinase (ALK) inhibitors, treatment options for

methodsThe cohort comprised eight patients with AP-IMT treated with crizotinib and surgery. Outcome measures were progression-free and overall survival after commencing crizotinib, treatment-related toxicities, features associated with relapse, outcome after relapse, and outcome after ceasing crizotinib.

resultsThe median follow-up after commencing crizotinib was 3 years (range, 0.9 to 5.5 years). The major toxicity was neutropenia. All patients responded to crizotinib. Five were able to discontinue therapy without recurrence (median treatment duration, 1 year; range, 0.2 to 3.0 years); one continues on crizotinib. Two critically ill patients with initial complete response experienced relapse while on therapy. Both harbored

conclusionWe confirm acceptable toxicity and excellent disease control in patients with AP-IMT treated with crizotinib, which may be ceased without recurrence in most. Relapses occurred in two of three patients with

Identifiers

PMID32914017
PMCPMC7446396
OpenAlexW2946774095

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.